Analysts See $-0.17 EPS for MediWound Ltd. (MDWD)

May 13, 2018 - By Michael Collier

Analysts expect MediWound Ltd. (NASDAQ:MDWD) to report $-0.17 EPS on May, 14.They anticipate $0.03 EPS change or 15.00 % from last quarter’s $-0.2 EPS. After having $-0.08 EPS previously, MediWound Ltd.’s analysts see 112.50 % EPS growth. The stock increased 3.48% or $0.2 during the last trading session, reaching $5.95. About 107,239 shares traded or 169.85% up from the average. MediWound Ltd. (NASDAQ:MDWD) has declined 19.69% since May 13, 2017 and is downtrending. It has underperformed by 31.24% the S&P500.

MediWound Ltd. (NASDAQ:MDWD) Ratings Coverage

Among 3 analysts covering Mediwound (NASDAQ:MDWD), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Mediwound had 5 analyst reports since November 16, 2017 according to SRatingsIntel. The rating was maintained by Wells Fargo with “Outperform” on Tuesday, March 20. The company was maintained on Thursday, November 16 by Oppenheimer. Oppenheimer maintained it with “Buy” rating and $10.0 target in Friday, December 8 report. The firm has “Outperform” rating by Oppenheimer given on Tuesday, March 20. On Thursday, November 16 the stock rating was maintained by SunTrust with “Buy”.

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products in Israel. The company has market cap of $160.93 million. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. It currently has negative earnings. The firm also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds.

More news for MediWound Ltd. (NASDAQ:MDWD) were recently published by:, which released: “MediWound Reports First Quarter 2018 Financial Results” on May 10, 2018.‘s article titled: “MediWound’s (MDWD) CEO Gal Cohen on Q1 2018 Results – Earnings Call Transcript” and published on May 12, 2018 is yet another important article.

MediWound Ltd. (NASDAQ:MDWD) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: